Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Otolaryngol Clin North Am ; 53(5): 765-777, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32564947

ABSTRACT

A literature review was conducted regarding the assessment and treatment of postoperative pain following surgery for obstructive sleep apnea (OSA). Given the risks of opioid use by patients with OSA, special attention to opioid risk reduction and avoidance is warranted in this population. The results of this review demonstrate the existence of a body of evidence that supports the use of nonopioid analgesics and nonpharmacologic approaches pain management. Strategies for managing postoperative pain should emphasize the use of local anesthetic infiltration, nonsteroidal antiinflammatory drugs, acetaminophen, topical analgesics, surgical wound cooling, and when necessary, safer opioid medications, such as tramadol and intranasal butorphanol.


Subject(s)
Analgesics, Opioid/administration & dosage , Pain Management/methods , Pain, Postoperative/drug therapy , Sleep Apnea, Obstructive/complications , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Opioid/adverse effects , Anesthetics, Local/administration & dosage , Humans , Pain, Postoperative/etiology , Postoperative Care/methods , Surgical Procedures, Operative/adverse effects
2.
Exp Cell Res ; 382(1): 111386, 2019 09 01.
Article in English | MEDLINE | ID: mdl-31075256

ABSTRACT

Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by many of these compounds, the authors are currently unaware of any instance whereby a cancer drug was developed with the UPR as the intended target. With the essential role of the UPR as a driving force in the genesis and maintenance of the malignant phenotype, a great number of pre-clinical studies have surged into the medical literature describing the ability of dozens of compounds to induce UPR signaling in a myriad of cancer models. The focus of the current work is to review the literature and explore the role of the UPR as a mediator of chemotherapy-induced cell death in squamous cell carcinomas of the head and neck (HNSCC) and oral cavity (OCSCC), with an emphasis on preclinical studies.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Squamous Cell/drug therapy , Drug Design , Molecular Targeted Therapy , Mouth Neoplasms/drug therapy , Neoplasm Proteins/metabolism , Squamous Cell Carcinoma of Head and Neck/drug therapy , Unfolded Protein Response/drug effects , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Drug Screening Assays, Antitumor , Drugs, Investigational/pharmacology , Eukaryotic Initiation Factor-2/metabolism , Humans , Mouth Neoplasms/metabolism , Phosphorylation , Protein Processing, Post-Translational , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Squamous Cell Carcinoma of Head and Neck/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...